A world-leading diversified cannabis and cannabinoid-based consumer product company.
In June 2018, during a period of strong growth in the cannabis sector, Canopy issued C$600MM of convertible notes with a conversion price of C$48.18. However, by late 2021, its stock price had declined significantly amid a challenging landscape.
Canopy looked to de-lever a portion of its balance sheet before the notes went current in July 2022 but faced several key regulatory and execution constraints.
Working closely with management, HudsonWest proposed several different options available to Canopy and helped evaluate the merits and impacts of each, given certain regulatory, legal and contractual constraints.
HudsonWest helped Canopy design an equitization of approximately 44% of the outstanding notes at a discount to par, with a floor price to protect the company from stock price fluctuations during execution.
In the equitization, Canopy was able to save over C$11MM in annual interest expense, move from a net debt position to a net cash position and strengthen its balance sheet.
The transaction also reiterated to the market the support of its largest shareholder, Constellation Brands, who participated in the transaction meaningfully — an important signal of confidence during a difficult period.
HudsonWest brings the same independence and depth to every engagement.